CONTRAINDICATIONS
ILARIS is contraindicated in patients with confirmed hypersensitivity to canakinumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Serious Infections
ILARIS has been associated with an increased risk of serious infections. Exercise caution when administering ILARIS to patients with infections...
ILARIS® (canakinumab) is an interleukin-1β blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes:
Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including:
Familial Cold Autoinflammatory Syndrome (FCAS)
Muckle-Wells Syndrome (MWS)...